CLG561

DRUG2 trials

Sponsors

Alcon Research

Conditions

Age-related Macular DegenerationGeographic Atrophy

Phase 1

Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

CompletedNCT01835015

Alcon ResearchAge-related Macular Degeneration

Start: 2013-05-31End: 2014-11-30Updated: 2016-03-25

Phase 2

CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)

CompletedNCT02515942

Alcon ResearchGeographic Atrophy

Start: 2015-09-25End: 2017-12-01Updated: 2019-05-30

Related Papers

Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells.

2021-03-1037 citations